Labcorp reaffirms 2026-2029 outlook, sees 5%-8% revenue CAGR

• Labcorp reaffirmed its 2026-2029 long-term outlook following CMS preliminary 2027-2029 Clinical Laboratory Fee Schedule rates under PAMA.
• Outlook targets 5%-8% compound annual revenue growth, 8.5%-11.5% compound annual adjusted EPS growth.
• Adjusted operating margin expected to expand 75-150 basis points by end-2029; free cash flow growth seen in line with adjusted earnings.
• Management expects to update on the CMS rate impact when it issues 2027 financial guidance in February 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000920148-26-000205), on September 22, 2026, and is solely responsible for the information contained therein.